[go: up one dir, main page]

ES2362525B8 - Medication formulation in the form of penetrating percutaneous needles. - Google Patents

Medication formulation in the form of penetrating percutaneous needles. Download PDF

Info

Publication number
ES2362525B8
ES2362525B8 ES200930820A ES200930820A ES2362525B8 ES 2362525 B8 ES2362525 B8 ES 2362525B8 ES 200930820 A ES200930820 A ES 200930820A ES 200930820 A ES200930820 A ES 200930820A ES 2362525 B8 ES2362525 B8 ES 2362525B8
Authority
ES
Spain
Prior art keywords
needles
hardness
drug
stiffness
medication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200930820A
Other languages
Spanish (es)
Other versions
ES2362525B1 (en
ES2362525A1 (en
Inventor
Arcadio Garcia De Castro Andrews
Raúl García Carrodeaguas
Niuris Acosta Contreras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azurebio SL
Original Assignee
Azurebio SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200930820A priority Critical patent/ES2362525B8/en
Application filed by Azurebio SL filed Critical Azurebio SL
Priority to CA2785315A priority patent/CA2785315A1/en
Priority to AU2010305368A priority patent/AU2010305368A1/en
Priority to AP2012006260A priority patent/AP2012006260A0/en
Priority to US13/500,279 priority patent/US9271927B2/en
Priority to CN2010800559557A priority patent/CN102647977A/en
Priority to EP10771379A priority patent/EP2485711A1/en
Priority to BR112012010443A priority patent/BR112012010443A2/en
Priority to PCT/EP2010/065106 priority patent/WO2011042542A1/en
Publication of ES2362525A1 publication Critical patent/ES2362525A1/en
Publication of ES2362525B1 publication Critical patent/ES2362525B1/en
Application granted granted Critical
Publication of ES2362525B8 publication Critical patent/ES2362525B8/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0069—Devices for implanting pellets, e.g. markers or solid medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/04—Acids; Metal salts or ammonium salts thereof
    • C08F220/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F220/56—Acrylamide; Methacrylamide
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/10—Esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/10—Esters
    • C08F222/1006—Esters of polyhydric alcohols or polyhydric phenols
    • C08F222/102—Esters of polyhydric alcohols or polyhydric phenols of dialcohols, e.g. ethylene glycol di(meth)acrylate or 1,4-butanediol dimethacrylate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/30—Nitriles
    • C08F222/32—Alpha-cyano-acrylic acid; Esters thereof
    • C08F222/321—Alpha-cyano-acrylic acid methyl ester
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/30—Nitriles
    • C08F222/32—Alpha-cyano-acrylic acid; Esters thereof
    • C08F222/322—Alpha-cyano-acrylic acid ethyl ester, e.g. ethyl-2-cyanoacrylate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/30—Nitriles
    • C08F222/32—Alpha-cyano-acrylic acid; Esters thereof
    • C08F222/324—Alpha-cyano-acrylic acid butyl ester
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/30—Nitriles
    • C08F222/32—Alpha-cyano-acrylic acid; Esters thereof
    • C08F222/326—Alpha-cyano-acrylic acid longer chain ester
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La invención se refiere a formulaciones de medicamentos para su administración en forma de agujas percutáneas penetrantes sólidas, “agujas inyectables”, fabricadas mediante procesos de polimerización por adición. El proceso de polimerización implica la transformación de una fase líquida que contiene monómeros en un cuerpo sólido monolítico, que contiene el medicamento, con la forma, dureza y rigidez requeridas para ser inyectadas en el tejido subcutáneo mediante sencillos dispositivos empujadores o inyectores. Estos procedimientos permiten la incorporación directa del medicamento a las agujas inyectables, o su incorporación en nano- o micro-partículas preformuladas para preservar la integridad y acción terapéutica del medicamento que contienen, así como de agentes modificadores de la velocidad de degradación, perfil de liberación del medicamento, dureza y rigidez, o inmunogenicidad.The invention relates to medicament formulations for administration in the form of solid penetrating percutaneous needles, "injectable needles", manufactured by addition polymerization processes. The polymerization process involves the transformation of a liquid phase that contains monomers in a monolithic solid body, which contains the medication, with the form, hardness and stiffness required to be injected into the subcutaneous tissue by simple pusher or injector devices. These procedures allow the direct incorporation of the drug into the injectable needles, or its incorporation in nano- or pre-formulated micro-particles to preserve the integrity and therapeutic action of the medicine they contain, as well as agents that modify the degradation rate, release profile of the drug, hardness and stiffness, or immunogenicity.

ES200930820A 2009-10-08 2009-10-08 Medication formulation in the form of penetrating percutaneous needles. Expired - Fee Related ES2362525B8 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES200930820A ES2362525B8 (en) 2009-10-08 2009-10-08 Medication formulation in the form of penetrating percutaneous needles.
PCT/EP2010/065106 WO2011042542A1 (en) 2009-10-08 2010-10-08 Formulation of drugs and vaccines in the form of percutaneous injectable needles
AP2012006260A AP2012006260A0 (en) 2009-10-08 2010-10-08 Formulation of drugs and vaccines in the form of percutaneous injectable needles.
US13/500,279 US9271927B2 (en) 2009-10-08 2010-10-08 Formulation of drugs and vaccines in the form of percutaneous injectable needles
CN2010800559557A CN102647977A (en) 2009-10-08 2010-10-08 Formulation of drugs and vaccines in the form of percutaneous injectable needles
EP10771379A EP2485711A1 (en) 2009-10-08 2010-10-08 Formulation of drugs and vaccines in the form of percutaneous injectable needles
CA2785315A CA2785315A1 (en) 2009-10-08 2010-10-08 Formulation of drugs and vaccines in the form of percutaneous injectable needles
AU2010305368A AU2010305368A1 (en) 2009-10-08 2010-10-08 Formulation of drugs and vaccines in the form of percutaneous injectable needles
BR112012010443A BR112012010443A2 (en) 2009-10-08 2010-10-08 formulation of drugs and vaccines as percutaneous injectable needles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200930820A ES2362525B8 (en) 2009-10-08 2009-10-08 Medication formulation in the form of penetrating percutaneous needles.

Publications (3)

Publication Number Publication Date
ES2362525A1 ES2362525A1 (en) 2011-07-07
ES2362525B1 ES2362525B1 (en) 2012-06-07
ES2362525B8 true ES2362525B8 (en) 2013-01-03

Family

ID=43662245

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200930820A Expired - Fee Related ES2362525B8 (en) 2009-10-08 2009-10-08 Medication formulation in the form of penetrating percutaneous needles.

Country Status (9)

Country Link
US (1) US9271927B2 (en)
EP (1) EP2485711A1 (en)
CN (1) CN102647977A (en)
AP (1) AP2012006260A0 (en)
AU (1) AU2010305368A1 (en)
BR (1) BR112012010443A2 (en)
CA (1) CA2785315A1 (en)
ES (1) ES2362525B8 (en)
WO (1) WO2011042542A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012103257A2 (en) * 2011-01-25 2012-08-02 The Regents Of The University Of California Transcutaneous multimodal delivery systems
US10251841B2 (en) * 2011-10-17 2019-04-09 Trustees Of Boston University Polymeric depots for localization of agent to biological sites
GB2498774A (en) * 2012-01-27 2013-07-31 Bruce Roser Glass-stabilised biological materials and syringe
JP6306523B2 (en) 2012-03-13 2018-04-04 ベクトン ディキンソン フランス Injection device having a miniaturized drug delivery part
CN103083659B (en) * 2013-01-18 2015-05-13 北京华夏兴洋生物科技有限公司 Preparation method and application of novel oil-free adjuvant
CN104248760B (en) * 2013-12-16 2021-07-23 普莱柯生物工程股份有限公司 Vaccine composition and preparation method and application thereof
KR20170055544A (en) * 2014-09-19 2017-05-19 옥슬러 리미티드 Ophthalmic drug compositions
KR102517757B1 (en) * 2015-05-13 2023-04-04 주식회사 엘지생활건강 Soluble Microneedle patch for saponin or saponin derivatives delivery
CN106177939B (en) * 2015-06-01 2021-01-19 普莱柯生物工程股份有限公司 Adjuvant for vaccine and application thereof
US10400105B2 (en) 2015-06-19 2019-09-03 The Research Foundation For The State University Of New York Extruded starch-lignin foams
CN106344920B (en) * 2015-07-16 2020-11-27 普莱柯生物工程股份有限公司 Adjuvant for vaccine and application thereof
EP4035711B1 (en) * 2016-03-15 2025-06-04 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
CN106177942A (en) * 2016-08-18 2016-12-07 山东滨州博莱威生物技术有限公司 A kind of for living paratyphoid vaccine for piglets adjuvant
CN106177944A (en) * 2016-08-18 2016-12-07 山东滨州博莱威生物技术有限公司 A kind of adjuvant for chicken Newcastle disease live vaccine
CN106466295A (en) * 2016-10-17 2017-03-01 四川华神兽用生物制品有限公司 A kind of vaccine diluent and preparation method and application
US11369677B2 (en) 2017-01-31 2022-06-28 Alf Lamprecht Use of nanoparticles for immunotherapy
CN107375921B (en) * 2017-06-12 2019-10-29 商丘美兰生物工程有限公司 A kind of glycyrrhizin liposome immunization adjuvant and preparation method thereof
JP6482604B2 (en) * 2017-06-22 2019-03-13 教裕 南郷 Inner skin dissolution type needle and needle device
WO2019053465A1 (en) 2017-09-15 2019-03-21 Oxular Limited Ophthalmic delivery device
GB201816547D0 (en) 2018-10-10 2018-11-28 Univ London Queen Mary Oncolytic virus for the treatment of cancer
GB201909280D0 (en) 2019-06-27 2019-08-14 Enesi Pharma Ltd Solid dose formulation
EP4048347A4 (en) * 2019-10-22 2024-01-10 Georgia Tech Research Corporation Methods for making microneedles using adjustment of component solubility in casting formulations
CN112426524A (en) * 2020-12-21 2021-03-02 中国医学科学院生物医学工程研究所 Application of plant polysaccharide as adjuvant in preparation of medicine for treating autoimmune disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901158A (en) 1969-05-13 1975-08-26 Thomas E Ferb Hypodermic projectile
US3857932A (en) * 1970-09-09 1974-12-31 F Gould Dry hydrophilic acrylate or methacrylate polymer prolonged release drug implants
CA1019638A (en) 1973-05-16 1977-10-25 John C. Muirhead Liquid injection projectile
US3948263A (en) 1974-08-14 1976-04-06 Minnesota Mining And Manufacturing Company Ballistic animal implant
US4326524A (en) 1980-09-30 1982-04-27 Minnesota Mining And Manufacturing Company Solid dose ballistic projectile
GB2091554B (en) * 1981-01-13 1984-09-12 Mitsui Toatsu Chemicals Rod like moulded drug
US4855134A (en) 1983-10-14 1989-08-08 Sumitomo Pharmaceuticals Company, Limited Sustained-release preparation
DE3484951D1 (en) * 1983-10-14 1991-09-26 Sumitomo Pharma EXTENDED PREPARATIONS WITH DELAYED DELIVERY.
WO1987000196A1 (en) 1985-07-09 1987-01-15 Quadrant Bioresources Limited Protection of proteins and the like
EP0265457A4 (en) * 1986-04-10 1989-07-26 Daratech Pty Ltd Vaccine and implant.
DK42093D0 (en) 1993-04-07 1993-04-07 Bukh Meditec METHOD OF ADMINISTRATION
US5542920A (en) 1994-09-12 1996-08-06 Delab Needle-less parenteral introduction device
NL9401534A (en) 1994-09-21 1996-05-01 Gijsbertus Gerardus Petrus Van Use of starch for parenteral applications.
IL122465A0 (en) 1995-06-07 1998-06-15 American Cyanamid Co Injection dart system
GB9612629D0 (en) 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
US6102896A (en) 1999-09-08 2000-08-15 Cambridge Biostability Limited Disposable injector device
DE10029694A1 (en) * 2000-06-16 2001-12-20 Basf Ag Use of radically-produced polymers, including block copolymers, in a very wide range of applications, eg coatings, toners, cosmetics, detergents, ink-jets, adhesives, moldings, films and fibers
PL360052A1 (en) 2000-10-13 2004-09-06 Cambridge Biostability Ltd. Composition and method for stable injectable liquids
GB2404865B (en) 2001-09-11 2005-09-28 Caretek Medical Ltd Novel drug delivery technology
MXPA05011311A (en) * 2003-04-25 2005-12-12 Kos Life Sciences Inc Formation of strong superporous hydrogels.
DK1940459T3 (en) * 2005-09-06 2014-05-26 Theraject Inc SOLID SOLUTION PERFORATOR CONTAINING ACTIVE SUBSTANCE PARTICLES AND / OR ACTIVE SUBSTANCED PARTICLES
GB2446780A (en) * 2007-02-22 2008-08-27 Glide Pharmaceutical Technolog An elongate parenteral injection body having an injection point of angle 10 to 40 degrees.
ATE544484T1 (en) 2007-10-09 2012-02-15 Azurebio S L INJECTION NEEDLE WITH WATER SOLUBLE BARRIERS FOR ADMINISTRATION OF MEDICINAL PRODUCTS AND VACCINES
US8465448B2 (en) 2008-02-18 2013-06-18 Azurebio S.L. Devices for the administration of drugs and vaccines in the form of injectable needles

Also Published As

Publication number Publication date
AU2010305368A1 (en) 2012-05-24
AP2012006260A0 (en) 2012-06-30
CN102647977A (en) 2012-08-22
EP2485711A1 (en) 2012-08-15
US9271927B2 (en) 2016-03-01
CA2785315A1 (en) 2011-04-14
BR112012010443A2 (en) 2019-01-08
US20120219589A1 (en) 2012-08-30
ES2362525B1 (en) 2012-06-07
WO2011042542A1 (en) 2011-04-14
ES2362525A1 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
ES2362525B8 (en) Medication formulation in the form of penetrating percutaneous needles.
AR064078A1 (en) SYSTEM OF ADMINISTRATION OF BIOCOMPATIBLE INJECTABLE INTRAOCULAR PHARMACOS, ITS USE TO PREPARE A MEDICINAL PRODUCT AND PROCESS FOR PREPARATION
AR085254A1 (en) INJECTION DEVICE
MX2013004406A (en) Treating diabetes melitus using insulin injections administered with varying injection intervals.
BR112013027674A2 (en) "uses of nanoparticle compositions, compositions comprising said nanoparticles and single needle catheter".
EP2600930A4 (en) INJECTION APPARATUS AND METHOD FOR DELIVERY OF MEDICAMENT
WO2016042163A3 (en) Ophthalmic drug compositions
MX2021004546A (en) Implantable drug delivery compositions and methods of use thereof.
BR112013004698A2 (en) pharmaceutical compositions comprising poh derivatives
WO2015095772A3 (en) Formulations and methods for targeted ocular delivery of therapeutic agents
MX388311B (en) Abuse resistant capsule
AR085260A1 (en) AUTO INJECTOR
Pahal et al. Microneedles for extended transdermal therapeutics: a route to advanced healthcare
BRPI0904961A2 (en) Implantable medical device, drug depot and method of administering a biologically active agent and clonidine or derivative thereof to a tissue and producing a drug depot
NI200700078A (en) CAP FOR DRUG ADMINISTRATION DEVICES
WO2013078257A3 (en) Implantable solid-liquig drug delivery apparatus, formulations, and methods of use
CO7151496A2 (en) Therapeutic agents for optimized subcutaneous administration
MX2017005461A (en) Injectable buprenorphine formulation.
WO2014036556A3 (en) Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine
PE20190351A1 (en) HUNTER'S SYNDROME THERAPEUTIC AGENT AND METHOD OF TREATMENT
MX2017008000A (en) Single use injection system.
MX2018000258A (en) Single use delivery device.
WO2014075203A8 (en) Nanoparticles with biodegradable and biocompatible polymer plga, loaded with the drug for human use pentoxifylline
BR112013010345A2 (en) diabetes mellitus treatment using insulin injections administered at varying injection intervals
AR082806A1 (en) STABLE PHARMACEUTICAL COMPOSITION

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2362525

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20120607

FD2A Announcement of lapse in spain

Effective date: 20210915